



Docket No.: 109536.204US1

PATENT/OFFICIAL

Law

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Ivan LIEBERBURG

Serial No. 10/644,935

Filed: August 21, 2003

:
:
:
:
:
:

Group Art Unit: 3762

Examiner: Not yet assigned

For: METHODS OF USING ZONISAMIDE AS AN ADJUNCTIVE THERAPY FOR
PARTIAL SEIZURES

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Copies of any cited U.S. Patents and U.S. Patent Publications are not being submitted in accordance with 37 CFR 1.98(a)(2)(i).

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No certification or fee is required.


In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

Serial No. 10/644,935

No fee is believed to be required, however, the Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 08-0219.

Respectfully submitted,

WILMER CUTLER PICKERING HALE AND DORR LLP

A handwritten signature in black ink, appearing to read "Edward D. Grief", is written over the printed name and registration number.

Edward D. Grief
Registration No. 38,898

1455 Pennsylvania Avenue, NW
Washington, DC 20004

TEL 202.942.8400 EDG/vyw

FAX 202.942.8484

Date: _____

February 25, 2005

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)				ATTY. DOCKET NO. 109536.204US1		SERIAL NO. 10/644,935	
				APPLICANT Ivan LIEBERBURG			
				FILING DATE August 21, 2003		GROUP 3762	

O I P E J C 174
 FEB 25 2005
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE

FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
	http://www.fda.gov/cder/drug/drugReactions/default.htm "Preventable Adverse Drug Reactions: A Focus on Drug Interactions," p. 1-42.
	Lazarou, J. <i>et al.</i> <u>JAMA</u> 279(15):1200-1205 (1998).
	Gurwitz, J.H. <i>et al.</i> <u>Am J. Med.</u> 109(2):87-94 (2000).
	French, J. <u>Epilepsia</u> 43(9):951-955 (2002).
	Ilo Leppik, <u>Epilepsia</u> 42(Suppl.4):1-6 (2001).
	Merkle, Elmar M. <i>et al.</i> , <u>European Radiology</u> (Germany) 12(8):1979-1992 (August 2002).
	Rogers, R.E., <i>et al.</i> , <u>Am. J. Surgery</u> 111(6):792-794 (1966).
	Ellison <i>et al.</i> , <u>J. Surg. Res.</u> 30(3):241-248 (March 1981).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.